.INVESTIGATION HIGHLIGHT.16 Oct 2024.
In the NIAGARA litigation, the add-on of perioperative durvalumab to standard therapy for muscle-invasive bladder cancer enhanced event-free and also on the whole survival, denoting a brand-new treatment possibility for this problem.